Not just ovaries—new name for PCOS reflects the condition's multisystem nature

medicalxpress - An estimated 1 in 8 women live with polycystic ovarian syndrome, commonly referred to as PCOS. However, the name is a bit of a misnomer; it suggests that the condition affects only the ovaries. In actuality, the condition is a broader metabolic and hormon…

AI Summary: Medical experts announced a name change for polycystic ovary syndrome to better reflect its multisystem effects rather than framing it solely as an ovarian disorder. The update aims to reduce stigma, encourage holistic management of metabolic and psychological comorbidities, and align terminology with current scientific understanding of the condition.

Stem cells have potent potential for diabetes treatment

medicalxpress - Humans have around 30 trillion cells in our adult bodies. Amazingly, each of these cells came from a handful of about 100 stem cells in the earliest days of development. The ability of these embryonic stem cells to turn into any cell type makes them pluri…

AI Summary: Researchers report stem cell–based approaches can replenish insulin‑producing cells and restore glycemic control in diabetes models, offering a potential path beyond daily insulin injections. Early findings suggest significant therapeutic promise, but scientists stress that safety, durability, and immune‑rejection hurdles must be cleared before these techniques graduate from experimental hope to standard care.

Nourish Secures $100M for Metabolic Health Clinic

Marissa Plescia / medcitynews - Nourish’s Series C round was led by Menlo Ventures, with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak and Operator Partners.The post Nourish Secures $10…

AI Summary: Nourish secured a $100 million funding round to expand its virtual metabolic-health and nutrition care model, doubling down on physician integration and broader clinical rollout. The company plans to scale tele-nutrition services and deepen provider partnerships to treat metabolic disease at home, aiming to convert weight and metabolic management into reimbursable medical care.

PCOS has been officially renamed PMOS, and it’s a momentous move

newscientist - PCOS will now be known as PMOS (polyendocrine metabolic ovarian syndrome), and for Alice Klein, who has the conditon, it's been a long time coming

AI Summary: Medical experts have rebranded polycystic ovary syndrome as "polyendocrine metabolic ovarian syndrome" (PMOS) to better reflect its metabolic and endocrine drivers and improve diagnosis and treatment for about 170 million affected women worldwide. The change follows years of debate over an inaccurate name and aims to reduce misdiagnosis and guide more targeted care—because calling it something sensible might actually help.

FDA approves 1st weekly basal insulin for Type 2 diabetes

Ella Jeffries / beckershospitalreview - The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise and is intended to reduce injecti…

AI Summary: The FDA approved the first once‑weekly basal insulin for adults with Type 2 diabetes, providing an alternative to daily injections and aiming to improve adherence and glycemic control. Regulators based the decision on trials showing comparable efficacy and safety to daily basal insulins, potentially reshaping diabetes management.